Toll-like receptor 2 stimulation of platelets is mediated by purinergic P2X1-dependent Ca²⁺ mobilisation, cyclooxygenase and purinergic P2Y1 and P2Y12 receptor activation

Summary

Toll-like receptor 2 (TLR2), which recognise and respond to conserved microbial pathogen-associated molecular patterns, is expressed on the platelet surface. Furthermore, it has recently been shown that the TLR2/1 agonist Pam3CSK4 stimulates platelet activation. The aim of the present study was to clarify important signalling events in Pam3CSK4-induced platelet aggregation and secretion. Platelet interaction with Pam3CSK4 and the TLR2/6 agonist MALP-2 was studied by analysing aggregation, ATP-secretion, [Ca²⁺]i mobilisation and thromboxane B2 (TxB2) production. The results show that Pam3CSK4 but not MALP-2 induces [Ca²⁺]i increase, TxB2 production, dense granule secretion and platelet aggregation. Preincubation of platelets with MALP-2 inhibited the Pam3CSK4-induced responses. The ATP-secretion and aggregation in Pam3CSK4-stimulated platelets was impeded by the purinergic P2X1 inhibitor MRS 2159, the purinergic P2Y1 and P2Y12 antagonists MRS 2179 and cangrelor, the phospholipase C inhibitor U73122, the calcium chelator BAPT-AM and aspirin. The calcium mobilisation was lowered by MRS 2159, aspirin and U73122 whereas the TxB2 production was antagonised by MRS 2159, aspirin and BAPT-AM. When investigating the involvement of the myeloid differentiation factor-88 (MyD88) -dependent pathway, we found that platelets express MyD88 and interleukin 1 receptor-associated kinase (IRAK-1), which are proteins important in TLR signalling. However, Pam3CSK4 did not stimulate a rapid (within 10 minutes) phosphorylation of IRAK-1 in platelets. In conclusion, the results show that Pam3CSK4-induced platelet aggregation and secretion depends on a P2X1-mediated Ca²⁺ mobilisation, production of TxA2 and ADP receptor activation. The findings in this study further support a role for platelets in sensing bacterial components.

Keywords

Infection - purinergic P2X1 receptor - atherosclerosis - MALP-2 - Pam3CSK4 - platelet - MyD88 - IRAK-1

• References

• 1 Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res 2002; 22: 913-922.
• 2 Bengtsson T, Grenegard M. Platelets amplify chemotactic peptide-induced changes in F-actin and calcium in human neutrophils. Eur J Cell Biol 1994; 63: 345-349.
• 3 Bengtsson T, Zalavary S, Stendahl O. et al. Release of oxygen metabolites from chemoattractant-stimulated neutrophils is inhibited by resting platelets: role of extracellular adenosine and actin polymerization. Blood 1996; 87: 4411-4423.
• 4 Bengtsson T, Fryden A, Zalavary S. et al. Platelets enhance neutrophil locomotion: evidence for a role of P-selectin. Scand J Clin Lab Invest 1999; 59: 439-449.
• 5 Herbertsson H, Bengtsson T. Role of platelets and the arachidonic acid pathway in the regulation of neutrophil oxidase activity. Scand J Clin Lab Invest 2001; 61: 641-649.
• 6 Bengtsson T, Grenegard M. Leucocyte activation by collagen-stimulated platelets in whole blood. Scand J Clin Lab Invest 2002; 62: 451-461.
• 7 Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-2494.
• 8 Yeaman MR. The role of platelets in antimicrobial host defense. Clin Infect Dis 1997; 25: 951-970.
• 9 Kalvegren H, Majeed M, Bengtsson T. Chlamydia pneumoniae binds to platelets and triggers P-selectin expression and aggregation: a causal role in cardiovascular disease?. Arterioscler Thromb Vasc Biol 2003; 23: 1677-1683.
• 10 Kalvegren H, Bylin H, Leanderson P. et al. Chlamydia pneumoniae induces nitric oxide synthase and lipoxygenase-dependent production of reactive oxygen species in platelets. Effects on oxidation of low density lipoproteins. Thromb Haemost 2005; 94: 327-335.
• 11 Kalvegren H, Fridfeldt J, Garvin P. et al. Correlation between rises in Chlamydia pneumoniae-specific antibodies, platelet activation and lipid peroxidation after percutaneous coronary intervention. Eur J Clin Microbiol Infect Dis 2008; 27: 503-511.
• 12 Kalvegren H, Andersson J, Grenegard M. et al. Platelet activation triggered by Chlamydia pneumoniae is antagonized by 12-lipoxygenase inhibitors but not cyclooxygenase inhibitors. Eur J Pharmacol 2007; 566: 20-27.
• 13 Nylander M, Lindahl TL, Bengtsson T. et al. The periodontal pathogen Porphyromonas gingivalis sensitises human blood platelets to epinephrine. Platelets 2008; 19: 352-358.
• 14 Shiraki R, Inoue N, Kawasaki S. et al. Expression of Toll-like receptors on human platelets. Thromb Res 2004; 113: 379-385.
• 15 Cognasse F, Hamzeh H, Chavarin P. et al. Evidence of Toll-like receptor molecules on human platelets. Immunol Cell Biol 2005; 83: 196-198.
• 16 Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511.
• 17 Rex S, Beaulieu LM, Perlman DH. et al. Immune versus thrombotic stimulation of platelets differentially regulates signalling pathways, intracellular protein-protein interactions, and alpha-granule release. Thromb Haemost 2009; 102: 97-110.
• 18 Blair P, Rex S, Vitseva O. et al. Stimulation of Toll-like receptor 2 in human platelets induces a thromboinflammatory response through activation of phosphoinositide 3-kinase. Circ Res 2009; 104: 346-354.
• 19 Berg M, Offermanns S, Seifert R. et al. Synthetic lipopeptide Pam3CysSer(Lys)4 is an effective activator of human platelets. Am J Physiol 1994; 266: C1684-1691.
• 20 Ward JR, Bingle L, Judge HM. et al. Agonists of toll-like receptor (TLR)2 and TLR4 are unable to modulate platelet activation by adenosine diphosphate and platelet activating factor. Thromb Haemost 2005; 94: 831-838.
• 21 Zhang G, Han J, Welch EJ. et al. Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 and the cGMP-dependent protein kinase pathway. J Immunol 2009; 182: 7997-8004.
• 22 Welin A, Winberg ME, Abdalla H. et al. Incorporation of Mycobacterium tuberculosis lipoarabinomannan into macrophage membrane rafts is a prerequisite for the phagosomal maturation block. Infect Immun 2008; 76: 2882-2887.
• 23 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
• 24 Jurk K, Kehrel BE. Platelets: physiology and biochemistry. Semin Thromb Hemost 2005; 31: 381-392.
• 25 Takeda K, Takeuchi O, Akira S. Recognition of lipopeptides by Toll-like receptors. J Endotoxin Res 2002; 8: 459-463.
• 26 Takeuchi O, Akira S. Toll-like receptors; their physiological role and signal transduction system. Int Immunopharmacol 2001; 1: 625-635.
• 27 Gachet C. P2 receptors, platelet function and pharmacological implications. Thromb Haemost 2008; 99: 466-472.
• 28 Grenegard M, Vretenbrant-Oberg K, Nylander M. et al. The ATP-gated P2X1 receptor plays a pivotal role in activation of aspirin-treated platelets by thrombin and epinephrine. J Biol Chem 2008; 283: 18493-18504.
• 29 Skoglund C, Wettero J, Skogh T. et al. C-reactive protein and C1q regulate platelet adhesion and activation on adsorbed immunoglobulin G and albumin. Immunol Cell Biol 2008; 86: 466-474.
• 30 Arancibia SA, Beltran CJ, Aguirre IM. et al. Toll-like receptors are key participants in innate immune responses. Biol Res 2007; 40: 97-112.